P01 Administrative Core

P01 行政核心

• 批准号: 10226284
• 负责人: Cesar Augusto Arias
• 金额: $ 15.6万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10226284
• 关键词: Accountability; Address; Advisory Committees; Agriculture; Antibiotic Resistance; Antibiotics; Antimicrobial Resistance; Benchmarking; Budgets; Clinical; Clinical Data; Clostridium difficile; Collaborations; Combating Antibiotic Resistant Bacteria; Communication; Critical Illness; Data; Decision Making; Development; Diagnostic; Disease Progression; Disputes; Effectiveness; Ensure; Enterobacteriaceae; Extended-spectrum β-lactamase; Genomics; Goals; Government; Home; Human Resources; Immunocompromised Host; Industrialization; Infection; Intensive Care Units; Leadership; Life; Liquid substance; Logistics; Mediating; Medical; Medical center; Minor; Modern Medicine; Monitor; Online Systems; Operations Research; Organism; Pathogenicity; Patients; Persons; Phenotype; Positioning Attribute; Process; Productivity; Program Reviews; Progress Reports; Proteomics; Public Health; Quality Control; Regimen; Research; Research Activity; Research Personnel; Research Project Grants; Resolution; Sampling; System; Techniques; Texas; Therapeutic; Translating; United Nations; United States National Institutes of Health; Vancomycin resistant enterococcus; Work; carbapenemase; clinical practice; commensal microbes; conflict resolution; data management; data sharing; functional genomics; gastrointestinal; gut colonization; gut microbiota; high risk; improved outcome; insight; meetings; metabolomics; microbiota; microorganism; mortality; multi-drug resistant pathogen; novel; outcome prediction; pathogen; programs; sample collection; success; synergism; treatment strategy

ABSTRACT (Administrative Core) The clinical introduction of antibiotics in 1930s-40s represented a major medical breakthrough enabling many advances in modern medicine, agriculture and industrial practice. Unfortunately, the rise of antibiotic-resistant microorganisms globally is now considered one of the most challenging public health threats of the 21st century. The call for action against the threat of antibiotic resistance has now reached the highest level of government including the Office of the US President (with the creation of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) and the initiative for global action by the United Nations, among others. Vancomycin-resistant enterococci (VRE), Enterobacteriaceae carrying extended spectrum β-lactamases and carbapenemases (ESBL-E/CRE), and Clostridiodes difficile are particularly concerning for high-risk patients who are immunocompromised and/or admitted to intensive care units (ICUs). Having the potential to cause life- threatening infections, particularly in those patients who have already been subjected to multiple antibiotic regimens, each of these organisms colonize the intestines, and their presence impacts subsequent colonization by other pathogens further contributing to serious disease progression and even mortality in these high-risk patients. Although these pathogens have been studied in isolation, elucidation of the dynamic interactions between pathogens and commensal gut microbiota and their implication for predicting outcomes and, thus, treatment strategies is more urgent than ever and requires a strategic, coordinated effort. The Texas Medical Center in Houston, Texas is home to several world leaders in antimicrobial resistance research and clinical practice with patient access and tremendous expertise in the cutting-edge genomic and phenotypic techniques who are uniquely positioned to perform concerted and synergistic systems-level studies of the multiple players that must be understood to address this challenge. These experts have recognized this exceptional opportunity and the strength of addressing the critical and unmet challenge through the formation of a multi-institutional collaborative research program Dynamics of Colonization and Infection by Multidrug- Resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE). Crucial for the effectiveness of this multi-institutional research effort, is dedicated centralized administrative oversight and support. The Administrative Core will serve as the central “hub” for program oversight, accountability, communication, and project/process coordination for the three Projects and the Functional Genomics Core. To achieve these goals, the Administrative Core will provide integrative accountability and oversight through the Executive Leadership Team and the Internal and External Advisory Committees, and administrative support for all project leaders, research personnel, key collaborators and advisors, and institutional administrative liaisons.

摘要（行政核心）